Skip to main content

Table 2 Baseline characteristics of patients with prostate cancer according to Ki67 CTC status

From: Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

Characteristic

Ki67 CTC-negative patients (no Ki67 + ve CTCs) (%)

Ki67 CTC-positive patients (≥1 Ki67 + ve CTC) (%)

Total patient numbers

28

23

Age, years

 Median

79.5

72

 Range

63–90

52–89

Number of metastasic sites

 1

12/28 (42.9)

8/23 (34.8)

 2

10/28 (35.7)

8/23 (34.8)

 3+

4/28 (14.3)

7/23 (30.4)

 Not stated

2/28 (7.1)

0/23 (0)

Metastasic sites

  

 Lymph Nodes alone

0/28 (0)

0/23 (0)

 Bone alone

12/28 (42.9)

8/23 (34.8)

 Bone and lymph nodes

8/28 (28.6)

5/23 (21.7)

 Visceral/multiple sites

6/28 (21.4)

10/23 (43.5)

 Unknown/Not stated

2/28 (7.1)

0/23 (0)

Treatment at time of 1st CTC specimen

 Cabazitaxel

0/28 (0)

6/23 (23.1)

 Docetaxel

6/28 (21.4)

3/23 (13)

 Abiraterone

13/28 (46.4)

11/23 (47.8)

 Others/Not stated

9/28 (32.1)

3/23 (13)

Line of treatment at time of 1st CTC specimen

 1

5/28 (17.9)

3/23 (13)

 2

8/28 (28.6)

5/23 (21.7)

 3+

3/28 (10.7)

7/23 (30.4)

 Not stated

12/28 (42.9)

8/23 (34.8)

Previous treatments

 Primary surgery

5/28 (17.9)

3/23 (13)

 Primary radiotherapy

6/28 (21.4)

5/23 (21.7)

 Docetaxel

21/28 (75)

20/23 (87)

 Enzalutamide

1/28 (3.6)

0/23 (0)

 Cabazitaxel

1/28 (3.6)

0/23 (0)

 Abiraterone

2/28 (7.1)

5/23 (21.7)

Total CTC levels at baseline

 Mean

12.9

92.8

 Range

0–79

2–316